Moore Paul Andrew
Chief Scientific Officer
Moore Paul Andrew has filed 3 SEC Form 4 filings (10 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Nov 16, 2026.
On the most recent filing, Moore Paul Andrew is listed as Chief Scientific Officer at Zymeworks Inc. Inside the rolling window, Moore Paul Andrew reported no open-market purchases and 3 open-market sales totaling $1.8M in ZYME. The largest disclosed transaction in the window is a sale of 39,741 ZYME shares on Nov 13, 2026, worth $1.0M.
Companies traded
Other insiders at ZYME
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.8M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Moore Paul Andrew made?
Moore Paul Andrew has filed 3 SEC Form 4 filings (10 transaction rows) across 1 company since 2026.
Which companies does Moore Paul Andrew trade?
Moore Paul Andrew has filed SEC Form 4 disclosures for 1 company, including ZYME.
When was Moore Paul Andrew's most recent SEC Form 4 filing?
Moore Paul Andrew's most recent SEC Form 4 filing on Tracefour is dated Nov 16, 2026.
What is Moore Paul Andrew's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Moore Paul Andrew is listed as Chief Scientific Officer.
What is Moore Paul Andrew's total buy and sell value in the current window?
Inside the rolling retention window, Moore Paul Andrew bought $0 and sold $1.8M based on SEC Form 4 filings.
What was Moore Paul Andrew's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 39,741 ZYME shares on 2026-11-13, worth $1.0M, per SEC Form 4 filings.